Trevena announces successful completion of Phase 1 study of TRV250 for acute migraine Pharmaceutical Investing
Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients Pharmaceutical Investing
European CHMP Adopts Positive Opinion for Yescarta (axicabtagene ciloleucel) Pharmaceutical Investing
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Pharmaceutical Investing
ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID (Pimavanserin) Pharmaceutical Investing
Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS (eflapegrastim) Data Pharmaceutical Investing
Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study Pharmaceutical Investing
Agilent Technologies to Expand Biopharma Consumables Portfolio with Acquisition of ProZyme Medical Device Investing
XELJANZ (tofacitinib citrate) Receives Marketing Authorisation in the European Union for Active Psoriatic Arthritis Pharmaceutical Investing
PreveCeutical Announces the Closing of Oversubscribed Non-Brokered Private Placement Biotech Investing
Health Canada Approves PrSYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis Genetics Investing
